Molecular Partners AGMLLCF 25 Net Current Asset Value is $2.16 as of Mar. 2026, which is 23% above its 10-year median of 1.76. GuruFocus rates MLLCF with a GF Score™ of 25/100 and a GF Value™ of $0.42 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 946 Biotechnology companies, Molecular Partners AG ranks better than 79.7% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Molecular Partners AG's net current asset value per share for the quarter that ended in Mar. 2026 was $2.16.
The historical rank and industry rank for Molecular Partners AG's Net Current Asset Value or its related term are showing as below:
MLLCF'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.66 Med: 1.76 Max: 12.47
Current: 1.88
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Molecular Partners AG was 12.47. The lowest was 0.66. And the median was 1.76.
MLLCF's Price-to-Net-Current-Asset-Value is ranked better than 79.7% of 946
companies
in the Biotechnology industry
Industry Median: 4.72
vs MLLCF: 1.88
Molecular Partners AG (OTCPK:MLLCF) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Molecular Partners AG Net Current Asset Value Related Terms
Molecular Partners AG Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Molecular Partners AG's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Molecular Partners AG Net Current Asset Value Chart
MLLCF vs VRTX, REGN, ALNY: Net Current Asset Value Comparison
For the Biotechnology subindustry, Molecular Partners AG's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Molecular Partners AG Price-to-Net-Current-Asset-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Molecular Partners AG's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Molecular Partners AG's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of $2.16 mean?
Molecular Partners AG (MLLCF) has a Net Current Asset Value of $2.16 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Molecular Partners AG and its competitors. This is 23% above median its historical median of 1.76. Over the past decade, Molecular Partners AG's Net Current Asset Value has ranged from 0.66 to 12.47. According to the industry distribution chart, Molecular Partners AG ranks #192 out of 946 companies in the Biotechnology industry, placing it in the top 20.3%.
Is Molecular Partners AG's Net Current Asset Value too high?
Molecular Partners AG's current Net Current Asset Value of $2.16 is 23% above median its 10-year median of 1.76. Over the past 10 years, this metric has ranged from a low of 0.66 to a high of 12.47. The Biotechnology industry median Net Current Asset Value is 4.72. Molecular Partners AG's value of $2.16 is 54.2% below this industry median. Based on the distribution chart, Molecular Partners AG ranks #192 out of 946 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Molecular Partners AG has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Molecular Partners AG's Net Current Asset Value compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Molecular Partners AG ranks #192 out of 946 companies for Net Current Asset Value. This places Molecular Partners AG in the top 20% of its industry — outperforming the majority of peers. The industry median Net Current Asset Value is 4.72. Molecular Partners AG's value of $2.16 is 54.2% below this benchmark. Historically, Molecular Partners AG's own Net Current Asset Value has ranged from 0.66 to 12.47 over the past decade. While the company's 10-year median is 1.76 vs. the industry median of 4.72, Molecular Partners AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Biotechnology company?
The median Net Current Asset Value among Biotechnology companies is 4.72, based on 946 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Molecular Partners AG's current Net Current Asset Value of $2.16 is 54.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Molecular Partners AG and its competitors. For the Biotechnology industry, the median Net Current Asset Value is 4.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Molecular Partners AG's current Net Current Asset Value is $2.16, which is 23% above median its own 10-year median of 1.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Molecular Partners AG stock overvalued right now?
Based on GuruFocus' analysis, Molecular Partners AG (MLLCF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.42, compared to a current price of $3.60 — trading 757.1% above its estimated fair value. The current Net Current Asset Value is $2.16, which is 23% above median its 10-year median of 1.76 and 54.2% below the Biotechnology industry median of 4.72. Molecular Partners AG's overall GF Score™ is 25/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Molecular Partners AG (MLLCF), the current Net Current Asset Value is $2.16 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Molecular Partners AG (MLLCF) Overvalued in 2026?
Based on GuruFocus' analysis, Molecular Partners AG stock appears to be overvalued.
The current stock price of $3.60 is trading 757.1% above its estimated GF Value™ of $0.42.
GuruFocus considers Molecular Partners AG to be Significantly Overvalued.
Key valuation signals for MLLCF:
Net Current Asset Value: $2.16 (23% above median its 10-year median of 1.76)
GF Value™: $0.42 vs. price of $3.60 (757.1% above fair value)
Industry Position: 54.2% below the Biotechnology median (#192 of 946)
No single metric tells the full story. See the MLLCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
25GF Score
Get the complete analysis for MLLCF
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MLLCF has been successfully added to your 
